RxDoctor Payments Data

Jonathan Datar, MD

Neurology · Denver, CONPI 1316333016

Payments from drug & device makers

$25,095in general payments, 2019–2025

Across 981 payments — averaging $25.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$4K
  • AbbVie$3K
  • EMD Serono, Inc.$3K
  • Novartis$2K
  • TG Therapeutics, Inc.$1K
  • Sanofi$1K
  • plus $11K from 45 others

What the payments were for

  • Food & beverage$24,79199%
  • Education$3041%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,095 in reported general payments places this provider in the 75th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Medicare billing

Part B allowed, 2024
$50,360
Medicare patients
122
Services billed
1,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate11$101,816
Nurtec OdtRimegepant Sulfate32$47,256
Emgality PenGalcanezumab-Gnlm30$28,833
Aimovig AutoinjectorErenumab-Aooe26$27,775
Glatiramer Acetate18$25,314
Ajovy AutoinjectorFremanezumab-Vfrm23$21,612
Dalfampridine ErDalfampridine63$20,608
BriviactBrivaracetam11$14,862
Lacosamide33$1,720
Carbamazepine ErCarbamazepine18$1,717
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine16$1,474
Dimethyl Fumarate11$1,231
Baclofen80$1,033
Gabapentin68$918
Memantine Hcl55$917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$3,818$101,81611 claims
PfizerNurtec Odt$391$47,25632 claims
UCB, Inc.Briviact$902$14,86211 claims
Upsher-smith Laboratories LLCTopiramate$78$10626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 334 neurology providers in Colorado.

Other neurology in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →